Speaker(s): 

Kent Vrana, PhD, FAAAS, Staff Member, Penn State Medical Marijuana Academic Clinical Research Center- has reported the following disclosure: PA Options for Wellness (Pennsylvania-approved medical marijuana company) ["Research Grant"].

Moderator(s): 

Brian Piper, PhD, Staff Member, Geisinger Commonwealth School of Medicine - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• defend the statement that exogenous cannabinoids access endogenous pharmacodynamic and pharmacokinetic systems.  
• identify potential health benefits and risks associated with the use of cannabis and unregulated cannabinoids. 
• explore real-world examples of drug-drug interactions between cannabinoids and prescription drugs.    

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

F. Daniel Davis, PhD, HEC-C and Thomas Davis, MD have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.